hsa-mir-662: Hsa-mir-662 is a microRNA that has been studied in various contexts. It has been found to be differentially expressed in human oocytes, with down-regulation in mature oocytes compared to immature oocytes [PMC4919285]. In a study analyzing differentially expressed miRNAs in glioblastoma, hsa-mir-662 was associated with different subtypes of the disease [PMC8911495]. Additionally, hsa-mir-662 has been identified as a potential regulator of CREB1, a transcription factor [PMC8629660]. It has also been found to be one of the miRNAs associated with alterations in metabolic pathways and the development of obesity [PMC6275070]. Furthermore, hsa-mir-662 has been included as one of the miRNAs used for predicting patient outcomes in a subtype of glioblastoma [PMC3917617]. In another study, hsa-mir-662 was found to be located within a seed region SNP, indicating its potential role in genetic variations [PMC4013412]. Changes in expression patterns of hsa-mir-662 have also been observed after exposure to low and high doses of X-ray radiation [PMC3424689]. Moreover, hsa-mir-662 has been identified as one of the miRNAs that showed differential expression levels between control and proliferative diabetic retinopathy patients [PMC7409134]. Overall, these studies highlight the diverse roles and associations of hsa-mir-662.

MIR662: MIR662 is an intragenic microRNA that is located in a non-coding exon sequence of the mesothelin-like gene [PMC4017260]. In a study, SCRIB, MIR662, and BARD1 were found to have higher frequencies of mutations (7.9%, 7.4%, and 5.3% respectively) compared to well-known mutational hotspots [PMC4017260]. These findings suggest the potential involvement of these genes in the pathogenesis of MPN [PMC4017260]. In addition to SCRIB, MIR662, and BARD1, other genes such as TCF12, FAT4, DAP3, POLG, and NRAS were also recurrently mutated in the cohort [PMC4017260]. The MIR662 variant rs74656628 may have a functional role that requires further investigation [PMC4017260]. The stem-loop coding region of MIR662 as well as MIR663 and MIR542 were found to harbor missense mutations [PMC4017260]. Furthermore, a mutation in the MIR17 gene was shown to affect the mature miRNA sequence downstream of its seed region [PMC4017260]. Mutations in other genes such as TET2, ASXL1, DNMT3A, RUNX1, EZH2 MLH1 MLH3 SF3B1 MSH6 MSH2 BARD1 KIT NRAS have also been reported in MPN cases [PMC9818412].